scholarly journals Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury

2014 ◽  
Vol 30 (9) ◽  
pp. 1472-1479 ◽  
Author(s):  
Manuel Praga ◽  
Angel Sevillano ◽  
Pilar Auñón ◽  
Ester González
Keyword(s):  
Acute Kidney Injury ◽  
Interstitial Nephritis ◽  
Clinical Presentation ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
Common Cause

scholarly journals Rifampicin Induced Acute Interstitial Nephritis in a Patient with Tubercular Lymphadenitis: A Case Report

2018 ◽  
Vol 8 (3) ◽  
pp. 257-259
Author(s):  
Hafsa Hassan Khan ◽  
Muhammad Abdur Rahim ◽  
Mehruba Alam Ananna ◽  
Tufayel Ahmed Chowdhury ◽  
Sarwar Iqbal
Keyword(s):  
Acute Kidney Injury ◽  
Case Report ◽  
Adverse Effects ◽  
Interstitial Nephritis ◽  
Case History ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
History Of ◽  
Tubercular Lymphadenitis ◽  
Prompt Diagnosis

Rifampicin is one of the most effective anti-tubercular agents. Among its rare adverse effects, acute interstitial nephritis (AIN) is noteworthy. Here, we describe the case history of a 55-year-old female with tubercular lymphadenitis who developed rifampicin induced AIN upon re-exposure and recovered satisfactorily without requiring steroids. Rifampicin induced AIN should be kept in mind when patients present with acute kidney injury as prompt diagnosis and discontinuation of the drug has excellent prognosis.Birdem Med J 2018; 8(3): 257-259

scholarly journals Time to Acute Kidney Injury in β-Lactam−Induced Acute Interstitial Nephritis

2020 ◽  
Vol 5 (7) ◽  
pp. 1068-1070 ◽  
Author(s):  
Benjamin Lazarus ◽  
Matthew R.P. Davies ◽  
Jason A. Trubiano ◽  
Rebecca Pellicano
Keyword(s):  
Acute Kidney Injury ◽  
Interstitial Nephritis ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis

scholarly journals Acute interstitial nephritis with immunotherapy; a growing entity?

2020 ◽  
Vol 9 (4) ◽  
pp. e35-e35
Author(s):  
John David Chetwood ◽  
Lin Lin Myat ◽  
Helen Lammi ◽  
Mani Panat ◽  
James Hughes
Keyword(s):  
Acute Kidney Injury ◽  
Renal Function ◽  
Interstitial Nephritis ◽  
Cancer Survival ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
Response To Treatment ◽  
Immune Mediated ◽  
Life Threatening ◽  
Potential Impact

We report a case of acute kidney injury (AKI) secondary to immune-mediated acute interstitial nephritis (AIN), with supporting diagnostic results and a successful response to treatment. This entity is gaining increasing recognition with the burgeoning use of immunotherapy agents in oncology. The timeline for the development of AIN from the initiation of immunotherapy varies, and may range in severity from asymptomatic to severe, organ-threatening and with life threatening consequences. Renal biopsy should be performed to confirm the diagnosis due to the potential impact of discontinuation of immunotherapy on cancer survival. Re-challenge with immunotherapy is reasonable once renal function recovers.

Acute interstitial nephritis: New agents for an old entity

2020 ◽  
Vol 4 (3) ◽  
pp. 100-104
Author(s):  
Filipa Cardoso ◽  
Rui Barata ◽  
David Navarro ◽  
Marco Mendes ◽  
Mário Góis ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Protein Kinase ◽  
Kidney Function ◽  
Interstitial Nephritis ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
Mitogen Activated Protein Kinase ◽  
Dermatologic Toxicity ◽  
Mitogen Activated Protein ◽  
Protein Kinase Kinase

A 73-year-old male diagnosed with metastasized malignant melanoma was started on combined therapy with dabrafenib and trametinib, but soon admitted with gastrointestinal intolerance. Blood tests revealed toxic hepatitis and acute kidney injury. Renal duplex Doppler ultrasound ruled out urinary and vascular obstruction and apart from a positive antinuclear antibody, other tests for acute kidney injury assessment were unremarkable. Urinary sediment microscopy showed dysmorphic red blood cells, in addition to yellow-pigmented casts. Kidney biopsy revealed signs of acute tubular necrosis and acute interstitial nephritis. Kidney function declined further, prompting the need for urgent hemodialysis. Treatment with dabrafenib and trametinib was stopped and corticosteroids were initiated, with a rapid beneficial effect on both the kidney function and liver toxicity. Hemodialysis was stopped after four sessions with a full recovery after 2 months of corticosteroids, with the dose being slowly tapered. Unfortunately, the patient died a few months later due to melanoma progression. Dual therapy with the combination of a B-Raf proto-oncogene inhibitor with a mitogen-activated protein kinase kinase inhibitor improves response rates and has been recently approved by the U.S. Food and Drug Administration, and while dermatologic toxicity is a common adverse effect, the association with acute renal failure has seldom been reported. To the best of our knowledge, there are only two published case reports of acute kidney injury in patients treated with combination of dabrafenib and trametinib and only one of them is biopsy proven. Further studies evaluating the incidence of acute kidney injury with the combination of B-Raf proto-oncogene and mitogen-activated protein kinase kinase inhibitors are warranted, and may provide new insights into the mechanisms underlying renal toxicity.

scholarly journals Biopsy-Proven Acute Tubular Necrosis due to Vancomycin Toxicity

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Farheen Shah-Khan ◽  
Marc H. Scheetz ◽  
Cybele Ghossein
Keyword(s):  
Acute Kidney Injury ◽  
Interstitial Nephritis ◽  
Acute Tubular Necrosis ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
Etiologic Factor ◽  
Clinical Use ◽  
Tubular Necrosis

Vancomycin (VAN) has been associated with acute kidney injury (AKI) since it has been put into clinical use in the 1950's. Early reports of AKI were likely linked to the impurities of the VAN preparation. With the advent of the more purified forms of VAN, the incidence of AKI related to VAN were limited to acute interstitial nephritis (AIN) or as a potentiating agent to other nephrotoxins such as Aminoglycosides. VAN as the sole etiologic factor for nephrotoxic acute tubular necrosis (ATN) has not been described. Here, we report a case of biopsy-proven ATN resulting from VAN.

scholarly journals Letrozole-Induced Acute Interstitial Nephritis

2020 ◽  
pp. 1-3
Author(s):  
Prianka Puri ◽  
M Fadia ◽  
Prianka Puri ◽  
Simon Jiang ◽  
Wajih Z
Keyword(s):  
Acute Kidney Injury ◽  
Aromatase Inhibitor ◽  
Interstitial Nephritis ◽  
Renal Damage ◽  
Oral Prednisone ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
Class Effect ◽  
Case Presentation ◽  
Chemotherapy Agents

Background: Acute interstitial nephritis is often associated with drug therapy. It can be a common cause of acute kidney injury, traditional chemotherapy agents have been associated with various forms of renal damage, but this is not commonly seen with anti-hormone therapy. Here we report a case of aromatase inhibitor associated acute interstitial nephritis with the use of letrozole. Case Presentation: We present the case of an 84-year-old female commended on letrozole for the management of estrogen sensitive breast cancer. The patient developed oliguric acute kidney injury 3-weeks after initiation, with a creatinine rise to 1069µmol/L, from a previously normal baseline. She had no response to hydration and underwent a renal biopsy which demonstrated acute interstitial nephritis. She was commended on 4 weeks of oral prednisone starting at 20mg with a tapering dose. Renal function returned to baseline on discharge and her aromatase inhibitor was ceased. Conclusions: This is the first reported case of letrozole induced acute interstitial nephritis. It appears the disease was steroid responsive however it is unclear if this is a class effect of aromatase inhibitors or letrozole alone.

Acute interstitial nephritis secondary to vedolizumab

2021 ◽  
Vol 14 (11) ◽  
pp. e243568
Author(s):  
Nicholas Simpson ◽  
John Paul Seenan ◽  
Rajan Patel ◽  
David Kipgen
Keyword(s):  
Acute Kidney Injury ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Maintenance Therapy ◽  
Renal Dysfunction ◽  
Interstitial Nephritis ◽  
Side Effect ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis

We present a patient with an acute kidney injury thought secondary to acute interstitial nephritis as a result of vedolizumab maintenance therapy for Crohn’s disease. This appears to be a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of renal dysfunction.

scholarly journals Acute Interstitial Nephritis: A Rare and Unusual Side Effect of Omalizumab

2020 ◽  
Vol 8 ◽  
pp. 232470962094689
Author(s):  
Rocky Yang ◽  
Leila Moosavi ◽  
Sabitha Eppanapally ◽  
Ayham Aboeed ◽  
Augustine Munoz
Keyword(s):  
Drug Therapy ◽  
Interstitial Nephritis ◽  
Immunoglobulin E ◽  
Persistent Asthma ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis ◽  
Systemic Diseases ◽  
Common Cause ◽  
Humanized Monoclonal Antibody ◽  
Severe Persistent Asthma

Acute interstitial nephritis (AIN) is a relatively common cause of acute kidney injury with etiologies that include drug therapy, infections, and systemic diseases. Of these etiologies, drug therapy accounts for ~70% of AIN cases. Although any drug can cause AIN, there are no reported cases of AIN caused by omalizumab, a humanized monoclonal antibody that binds to and inhibits circulating immunoglobulin E. In this article, we share the first reported case of AIN following administration of omalizumab for the treatment of moderate to severe persistent asthma.

Renal Parenchymal Malakoplakia with Acute Interstitial Nephritis Presented with Acute Kidney Injury

2015 ◽  
Vol 38 (1) ◽  
pp. 36 ◽  
Author(s):  
In Mee Han ◽  
Youn Kyung Kee ◽  
Eunyoung Lee ◽  
Choong-kun Lee ◽  
Seung Gyu Han ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Interstitial Nephritis ◽  
Kidney Injury ◽  
Acute Interstitial Nephritis
Sign in / Sign up

Export Citation Format

Share Document